Bioequivalence of Dabigatran Etexilate Polymorphs

Phase 1, randomised, double-blind trial of dabigatran in thromboembolism and Atrial fibrillation (AFib) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of total BIBR 953 ZW in plasma over the time interval from 0 extrapolated to infinity up to 72 hours and Maximum measured concentration of total BIBR 953 ZW in plasma up to 72 hours. Started Apr 2006; status: completed.